150 completed, 23 unknown, 15 terminated, 9 withdrawn. 66 Phase 3, 64 Phase 4, 35 Phase 1, 23 Phase 2, 20 Not applicable.
Follow Lansoprazole: new trials by email Literature Review of Lansoprazole trials Research Report on Lansoprazole
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects JP-1366 20 mg, Lansoprazole 30 mg Placebo, Clarithromycin 500mg, Amoxicillin 1000mg, Lansoprazole 30mg, JP-1366 20 mg Placebo, Clarithromycin 500mg, Amoxicillin 1000mg - H. Pylori Eradication Therapy | Phase 3 | Not yet recruiting | Onconic Therapeutics Inc. | 414 | 2026-11-01 | 2026-10-15 |
| Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer DWP14012 40mg (Fexuprazan), Lansoprazole 30mg - Gastric Ulcer | Phase 3 | Not yet recruiting | Daewoong Pharmaceutical Co. LTD. | 384 | 2026-10-15 | 2026-07-28 |
| Tegoprazan Versus Lansoprazole for Endoscopic Ulcer Healing in Bleeding Peptic Ulcers Tegoprazan tablet, Lansoprazole capsules - Peptic Ulcer Bleeding | Phase 2 | Recruiting | Universitas Indonesia | 162 | 2026-08-06 | 2026-08-21 |
| Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 as Maintenance Therapy in Subjects With Healed Erosive Esophagitis JP-1366 10 mg, Lansoprazole 15mg - Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD) | Phase 3 | Not yet recruiting | Onconic Therapeutics Inc. | 384 | 2026-08-01 | 2026-07-28 |
| Study to Evaluate the Efficacy and Safety of Fexuprazan in Prevention of NSAIDs Induced Peptic Ulcer Fexuprazan 20mg, Lansoprazole 15 mg placebo, Lansoprazole 15 mg - NSAID (Non-Steroidal Anti-Inflammatory Drug) | Phase 4 | Not yet recruiting | Daewoong Pharmaceutical Co. LTD. | 360 | 2026-04-01 | 2026-04-16 |
| A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) Linaprazan glurate 50 mg Twice Daily (BID), Linaprazan Glurate 50 mg Once Daily (QD), Lansoprazole 30 mg Once Daily (QD) - GERD (Gastroesophageal Reflux Disease) | Phase 3 | Completed | Cinclus Pharma Holding AB | 523 | 2025-09-11 | 2026-10-21 |
| The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection Lansoprazole, amoxicillin, clarithromycin - Helicobacter Pylori Infection | Phase 3 | Not yet recruiting | Assiut University | 70 | 2025-06-01 | 2025-05-09 |
| Tegoprazan And Lansoprazole Effectiveness in Bleeding Peptic Ulcer Treatment Tegoprazan, Lansoprazole - Peptic Ulcer Bleeding | Not applicable | Recruiting | Mario Steffanus | 162 | 2025-05-01 | 2025-05-29 |
| Efficacy of Gut-Brain Neuromodulators in the Treatment of Gastroesophageal Reflux Disease Flupentixol-Melitracen + Lansoprazole, Lansoprazole and placebo - Gastroesophageal Reflux Disease | Not applicable | Completed | RenJi Hospital | 164 | 2025-04-24 | 2025-11-18 |
| Efficacy of Gut-Brain Neuromodulators for Functional Dyspepsia Flupentixol-Melitracen + Lansoprazole, Lansoprazole - Functioanl Dyspepsia | Not applicable | Not yet recruiting | RenJi Hospital | 200 | 2025-04-10 | 2025-04-17 |
| Fexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy Fexuprazan 40mg, Lansoprazole 30mg - Acute Coronary Syndromes (ACS), Coronary Artery Disease (CAD) | Not applicable | Recruiting | SUK MIN SEO | 200 | 2024-10-24 | 2026-10-19 |
| Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer Ilaprazole, Lansoprazole, Ilaprazole Placebo - Peptic Ulcer | Phase 3 | Recruiting | Il-Yang Pharm. Co., Ltd. | 416 | 2024-07-23 | 2025-05-30 |
| Neuroregulators for the Treatment of Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities. Takepron, Zoloft 50Mg Tablet, Imipramine Pill - Gut-Brain Disorders, GERD Without Erosive Esophagitis | Not applicable | Recruiting | Hualien Tzu Chi General Hospital | 610 | 2024-04-02 | 2026-09-08 |
| A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer Avelumab, Aspirin, Lansoprazole - Breast Cancer | Phase 2 | Withdrawn | The Christie NHS Foundation Trust | 2023-12-01 | 2025-12-08 | |
| Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy Vonoprazan and Amoxicillin, Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole - Helicobacter Pylori Infection | Phase 4 | Completed | Fu Jen Catholic University Hospital | 337 | 2023-11-14 | 2026-02-17 |
| Efficacy of Fexuprazan for Prevention or Control of Gastritis Symptoms in Patients on Treatment With Systemic Steroids Lansoprazole, Fexuprazan Hydrochloride - Patients on Treatment With Systemic Steroids | Phase 4 | Completed | Yonsei University | 42 | 2023-11-07 | 2026-01-13 |
| Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding Proton Pump Inhibitors, No Proton Pump Inhibitors - Upper Gastrointestinal Hemorrhage | Phase 4 | Not yet recruiting | West China Hospital | 672 | 2023-10-01 | 2023-09-28 |
| A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121 Lansoprazole 15 mg, Lansoprazole 15mg/Calcium carbonate 600mg - Gastro Esophageal Reflux | Phase 1 | Completed | Addpharma Inc. | 24 | 2023-09-15 | 2024-08-01 |
| The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole) Lansoprazole 15 mg - Coronary Artery Disease | Phase 4 | Unknown | Daejeon St. Mary's hospital | 300 | 2023-05-01 | 2023-04-19 |
| Medicine-induced Cardiac Hemodialysis on COVID-19 Nifedipine 30 MG, Kangzhu BPCB0A-3A, Low Mobility - Severe Acute Respiratory Syndrome-related Coronavirus, Renal Dialysis | Phase 4 | Completed | Yang I. Pachankis | 1 | 2023-01-02 | 2023-02-03 |
Showing 20 of 212. Sign in to see all of them.
Gastroesophageal Reflux (49) · Heartburn (17) · Duodenal Ulcer (16) · Stomach Ulcer (16) · Peptic Ulcer (11) · Esophagitis, Peptic (9) · Laryngopharyngeal Reflux (6) · Esophagitis (4) · Helicobacter Infections (4) · Asthma (3) · Breast Neoplasms (3) · Diabetes Mellitus, Type 1 (3) · Dyspepsia (3) · Peptic Ulcer Hemorrhage (3) · Barrett Esophagus (2)
Takeda (46) · AstraZeneca (9) · HK inno.N Corporation (6) · Daewoong Pharmaceutical Co. LTD. (5) · National Taiwan University Hospital (5) · Seoul National University Hospital (4) · Shanghai Jiao Tong University School of Medicine (4) · First Affiliated Hospital of Zhejiang University (3) · Janssen Research & Development, LLC (3) · Novartis (3) · Onconic Therapeutics Inc. (3) · Phathom Pharmaceuticals, Inc. (3) · Teva Pharmaceuticals USA (3) · Cinclus Pharma Holding AB (2) · Emory University (2)
United States (69) · South Korea (32) · China (22) · Taiwan (17) · Japan (14) · Czechia (7) · Bulgaria (6) · Canada (6) · Poland (6) · United Kingdom (6) · Hungary (5) · Turkey (Türkiye) (5) · Indonesia (4) · Australia (3) · Germany (3)
Paula Fernstrom (4) · Lihua Wu, Doctor (3) · Anne Armstrong (2) · Han-Suk Kim, MD, PhD (2) · Hong Lu, M.D. (2) · Jyh-Ming Liou, MD (2) · Pingsheng Hu, Ph.D (2) · Alex Rabinovitch, MD (1)
PMID 19735233, PMID 21129076, PMID 20195905, PMID 23451835, PMID 24118079, PMID 18590344, PMID 18590345, PMID 19183157, PMID 19681809, PMID 27891632, PMID 28988197, PMID 29196436, PMID 39085080, PMID 11519503, PMID 12161727, PMID 12526935, PMID 15645403, PMID 15758000, PMID 16481828, PMID 17767471, PMID 17916545, PMID 18423628, PMID 18507843, PMID 19210298, PMID 19392864, PMID 19581810, PMID 20456300, PMID 20457157, PMID 20925534, PMID 20947881, PMID 20957498, PMID 21028753, PMID 21073392, PMID 21118280, PMID 21126648, PMID 21193359, PMID 21224838, PMID 21716130, PMID 21777974, PMID 21908799, PMID 22155561, PMID 22249527, PMID 22274684, PMID 22464259, PMID 22681960, PMID 22688850, PMID 23197288, PMID 23333143, PMID 23376004, PMID 23403682
2018 (3), 2019 (2), 2016 (1), 2017 (1), K23DK115827 (1), U01HL080450 (1)